Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | E75 |
Synonyms | |
Therapy Description |
NeuVax (E75) is a HER2-derived peptide vaccine that induces an anti-HER2 immune response, potentially resulting in decreased tumor recurrence (PMID: 18536917, PMID: 24907636). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
E75 | NeuVax|nelipepimut-S | HER2 (ERBB2) Vaccine 14 | NeuVax (E75) is a HER2-derived peptide vaccine that induces an anti-HER2 immune response, potentially resulting in decreased tumor recurrence (PMID: 18536917, PMID: 24907636). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01570036 | Phase II | E75 Sargramostim Trastuzumab | Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax | Completed | USA | 0 |
NCT02297698 | Phase II | Sargramostim Trastuzumab E75 | Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients | Completed | USA | 0 |
NCT01479244 | Phase III | E75 Sargramostim | Efficacy and Safety Study of NeuVax (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence | Completed | USA | ROU | POL | ISR | HUN | GBR | FRA | DEU | CAN | BGR | 3 |